Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Bullboard Posts
Comment by elgin1on May 19, 2020 10:06am
100 Views
Post# 31045484

RE:RE:RE:Results !

RE:RE:RE:Results !I was wondering when you were going to crawl out underneath the rock. The corrected cells that were inserted in the pouch were from Human patients dumba**. They were implanted in mice with the pouch. Once the pouch is shown to be safe with Fda trials, there will be a clinical study for Hemophilia which is $10 billion annual market. On top of that, since the endothelial cells are from the patient itself, there is NO need for immunosuppresion drugs.

This is significant news Bioteck. For a guy that apparently has a free shares ( yeah right) you seem bitter and disappointed. So where’s the pp? Your comment shows your personal hatred for the company that fired you. 

For all the longs, this is an excellent and ground breaking achievement . Let’s see what the patient trial results are from the Fda trials.
Bullboard Posts